Effect of physical exercise on pain thresholds and plasma beta-endorphins in patients with silent and symptomatic myocardial ischaemia by Droste, C. et al.
European Heart Journal (1988) 9 (Supplement N). 25-33
Effect of physical exercise on pain thresholds and plasma
beta-endorphins in patients with silent and symptomatic
myocardial ischaemia
C. DROSTE, H. MEYER-BLANKENBURG, M. W. GREENLEE* AND H. ROSKAMM
Rehabilitationszentrum fur Hen- und Kreislaufkranke, 7812 Bad Krozingen, and *Newologische Univer-
sitdtsklinik, Abt. Neurophysiologie 7800 Freiburg, F.R.G.
KEY WORDS: Silent myocardial ischaemia, endorphins, naloxone, experimental pain measurement, physical
exercise.
In a double-blind study, eight patients with symptomatic myocardial ischaemia and nine with asymptomatic
myocardial ischaemia were compared during physical exercise under naloxone (6 mg i.v.) or placebo. Plasma
beta-endorphin, cortisol and catecholamines were measured before exercise, during maximal exercise, and 10, 20
and 60 min after exercise. A tourniquet pain test (on the forearm, under control of transcutaneous PO2). and an
electrical pain test (intracutaneous electrode placed in the finger with the electrical stimulus under computer
control and two-interval forced-choice psychophysical technique) were performed before exercise as well as
immediately after, and 60 min after exercise. Plasma beta-endorphin levels increased significantly (P < 001)
during exercise in symptomatic and asymptomatic patient groups; every patient showed an increase on beta-
endorphins during and after exercise. However, the increase found in beta-endorphins during and after exercise
was significantly larger (P < 001) in asymptomatic than in symptomatic patients. After naloxone, this difference
was no longer evident. Angina pectoris during exercise was reported with less latency in symptomatic patients
(P < 005) and occurred in two of nine asymptomatic patients following naloxone. The time course of plasma
cortisol levels exhibited the same pattern as beta-endorphins with the same significant differences between symp-
tomatic and asymptomatic groups. Electrical pain thresholds, though on average higher in asymptomatic patients
(2-21 mA vs. 0-79 mA), were not affected by exercise or naloxone. Asymptomatic patients required more time to
reach pain thresholds in the tourniquet pain test (P <0-02). After exercise, tourniquet pain thresholds were
significantly lower (P < 001) under naloxone compared with placebo. The results suggest that there are quan-
titative differences in the endorphinergic regulation of pain in patients with symptomatic and asymptomatic
myocardial ischaemia.
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Figure I A schematic representation of the experimental design and time course of
the measurements made.
one day before participating in the experiments, all
patients were given a written explanation of the
general research aims and possible hazards involved
and were then requested to sign an informed consent,
which was complied with in all cases.
PATIENTS
A total of 17 men (mean age, 54 ± 7 years) with
angiographically proved coronary artery disease were
studied. All patients exhibited at least 75% stenosis
in at least one major coronary artery, all of whom
repeatedly demonstrated significant myocardial is-
chaemia (> 01 mV ST segment depression) in several
exercise tests. A total of seven had already suffered
an infarction. Eight patients exhibited symptomatic
myocardial ischaemia (i.e.. concomitant occurrence
of angina pectoris and ST segment depression during
exercise tests). These latter patients also reported the
occurrence of angina pectoris during their everyday
life whenever they failed to take medication. The
other nine patients had asymptomatic myocardial
ischaemia, which was indicated by the absence of
angina pectoris pain in the presence of ST segment
depression during several exercise tests. Seven of nine
patients reported an absence of angina pectoris in
everyday life despite severe ischaemia evident in 24 h
Holter monitoring. The other two patients reported
only mild complaints. Patients were excluded who
had any secondary diseases which could affect pain
sensibility (e.g.. polyneuropathy. diabetes, alcohol
addiction). In none of the patients had aortocoronary
bypass surgery or percutaneous transluminal cor-
onary angioplasty been performed. Symptomatic and
asymptomatic patients did not differ in vessel disease,
(symptomatic group: two with one-vessel disease, five
with two-vessel disease, one with three-vessel disease
and the asymptomatic group: one, four, and four,
respectively) or in left ventricular function (ejection
fraction; 58 + 5-73 symptomatic, 65 + 4-27 asympto-
matic patients).
PROCEDURE
The study consisted of three examinations con-
ducted on separate days but always in the morning
hours to control the possible effect of circadian
rhythms. First, a pretest when resting was performed
to determine pain thresholds and plasma beta-
endorphin levels. The pretest also served to allow the
patients to become accustomed to the laboratory
setting and the measurement procedure. The second
and third examinations were conducted in a strict
double-blind manner, where patients received either
6 mg naloxone or saline 5 min prior to the start of
exercise. Figure 1 describes the time course of the
investigation. Prior to the experiments, all medication
was withdrawn for a time period at least equal to
five times the medication's half-life.
PHYSICAL EXERCISE
Physical exercise was performed supine using a
commercially available bicycle ergometer (Elema
Schonander). A 12-channel ECG was continuously
registered. All patients commenced exercise at 50 W.
which was increased stepwise in 3-min segments each.
Generally three or four exercise segments were per-
formed. The criteria for termination of exercise was
angina pectoris pain no longer tolerable by the pa-
tient, exhaustion or attainment of a max. 0-4 mV ST
segment depression.
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Physical exercise and pain threshold 27
BLOOD PLASMA DETERMINATIONS AND NALOXONE VS.
PLACEBO
Blood was sampled using an intravenous cannula
in the cubital vein in the nonpreferred arm, which
was kept open with a slowly flowing saline solution.
The first blood sample was taken 30 minutes after
insertion of the cannula. During these 30 min the
patient was requested to remain lying down and rest
(Fig. 1). Blood samples were taken 10 min prior to
exercise, at the point of maximal exertion, as well as
10, 20 and 60 min following termination of exercise.
Lactate was determined at each exercise level from
blood drawn from the ear lobe. Naloxone (Narcan,
DuPont Pharmaceuticals, 6 mg in 15 ml solution)
and placebo (15 ml 0-9% saline) were injected i.v. in
random order under strict double-blind control 5 min
prior to the start of exercise. With intravenous
injection of naloxone, the full effect is immediately
present and has a half-life of approximately 60
min[101. It can thus be assumed that at the time of
exercise the effect of naloxone was substantial. Blood
samples were drawn using chilled cannulas and were
transported in ice and centrifugated at +4°C. Plasma
was frozen at — 80°C. Care was taken to assure that
no more than 5 min elapsed between the time the
sample was drawn from the vein and the start of
centrifugation. Plasma beta-endorphins were deter-
mined using a highly specific radioenzymatic kit
(Allegro, Nichols Institute, U.S.A.). The sensitivity
of the assay is 10 pg/ml. Cross reactivity to human
beta-endorphin is 100%, to other substances very low
(human beta lipotropin 16%, all others < 003%).
The intra-assay variation coefficient is 4 1 % , inter-
assay variance 9%. Samples were tested twice to
control reliability, using the same kit for all samples
from the same patient to eliminate variance across
kits. Cortisol was determined via florescence polar-
ization immunoassay (Abbott TDx Cortisol). Epi-
nephrine and norepinephrine were determined using
high-performance liquid chromatography (HPLC-kit
BIO-RAD).
EXPERIMENTAL PAIN THRESHOLDS
Electrical pain thresholds were determined prior
to and directly after exercise, as well as 60 min fol-
lowing termination of exercise. An intracutaneous
stainless steel electrode was inserted into the tip of
the middle finger of the nonpreferred hand. Follow-
ing the procedure described by Bromm and co-
workers"'1 we first removed 1-2 mm of the dermis
with a manually operated dental drill. This reduced
the skin resistance substantially. The stimulus was
delivered via a specially designed electrical-stimulus
generator under computer control using a two-inter-
val forced-choice technique'121. A 10 ms constant-
current rectangular-wave impulse was presented
randomly in one of two temporal intervals delineated
by acoustic tones. The patients responded by pressing
one of two buttons whether they thought the stimulus
was presented in the first or second interval.
Depending on whether the response was right or
wrong, stimulus amplitude was reduced or increased
based on a maximum likelihood threshold search
algorithm (the best PEST'131). A threshold estimate
was obtained after 40 trials and the 75% correct-
response level on the estimated psychometric func-
tion was the criterion used for the threshold.
We used a modified form of the tourniquet pain
test'14' to measure ischaemic pain threshold levels
in the forearm. A manometer cuff was inflated to
200 mmHg on the upper preferred arm to occlude
bloodflow. Patients then engaged in a hand-grip
exercise (50% of maximal effort, which was deter-
mined using a Vigorimeter) at a predefined frequency
of 40 depressions/min. To assess quantitatively the
extent of ischaemia in the forearm, we measured
simultaneously the transcutaneous partial oxygen
tension (tcPO2) polarographically using the Oxy-
monitor (cf. Hellige'151). Tc PO2 gives an estimate
of the arterial PO2 and thus can be used as a correlate
of tissue ischaemia. While the patients engaged in
the hand-grip exercise they reported when they first
experienced pain in the working arm (threshold)
and when their point of subjective tolerance to the
induced pain (tolerance level) was reached.
CLINICAL PAIN MEASUREMENT
The investigation was conducted in a quiet, shielded-
off room to avoid any possible source of distraction.
All instructions were given by reciting a standardized
text and talking was prohibited during measurements.
The patient was requested to report whenever he felt
any angina pectoris and if the severity of angina
increased. The point in time of angina onset and
increment was recorded using a series of stop-
watches.
Results
For all patients exercise was so intense that the
maximal lactate levels exceeded in all cases the
anaerobic threshold of 4 mMl"1. No differences in the
extent and duration of exercise was found between
symptomatic and asymptomatic patient groups nor
between naloxone vs. placebo conditions (cf. Table
1). Furthermore, no significant group differences
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Table I Comparison of exercise parameters, laciate levels and elecirocardiographic variables in symptomatic (N = 8)
and asymptomatic (N = 9) patients following placebo and 6 mg naloxone
Max.
exercise
(W)
Symptomatic patients (N =
Placebo
Naloxone
116 ± 27
119 ± 22
Asymptomatic Patients (A'
Placebo
Naloxone
125 ± 35
122 ± 34
Duration
of exercise
(s)
= 8)
529 ± 202
539 ± 200
= 9)
487 ± 186
470 ± 192
Ma>c.
Lactate
(mMl
5-97 ±
6-22 ±
7-17 ±
6-84 ±
'I)
2-25
2-87
1-80
1-70
0-
0-
0-
0-
Max.
ST-|
(mV)
26 ± 0-
24 ± 0-
29 ± 0-
28 ± 0
11
10
15
14
Max.
Heart rate
(beats min'1)
123 ±
122 ±
128 ±
130 ±
24
20
15
13
Max.
Sys
193
193
184
182
±
±
±
±
blood
t.
29
23
15
14
Diast.
105 ±
104 ±
104 ±
104 ±
9
8
11
9
Max.
double
product
HF x RRS
23 968 ± 7387
23 734 ± 5766
23 719 ± 4323
23 695 ± 3335
were found for maximal lactate level, maximal ST
segment depression, maximal heart rate, maximal
systolic and diastolic blood pressure or maximal
double product.
PLASMA BETA-ENDORPHIN LEVELS
No significant differences were found between
symptomatic and asymptomatic patients on beta-
endorphin levels in plasma during rest. The pretest
(day 1) beta-endorphin resting values were in all
patients higher than on days 2 and 3, which was
probably a result of unspecific activation in the new
test situation. Asymptomatic patients exhibited
slightly higher values than did symptomatic patients
on day 1. On days 2 and 3 the resting values, meas-
ured after 30 min of rest, did not differ noticeably
between patient groups (maximal difference < 8%).
Plasma beta-endorphin levels increased significantly
during exercise in both symptomatic and asympto-
matic patient groups (Fig. 2). The maximal beta-
endorphin level was usually reached 10 min following
cessation of exercise. Original baseline levels were
usually obtained 60 min following exercise. An
analysis of the individual time course for each patient
indicated that every patient demonstrated an increase
in beta-endorphins during and after exercise. In the
symptomatic group, the mean increase in beta-endor-
phin levels was 37% of the baseline level (P < 001).
Asymptomatic patients exhibited a significantly
larger increase in beta-endorphins: at maximal exer-
tion the increase is 141% above baseline levels, and
212% above baseline 10 min after exercise cessation.
Twenty minutes after exercise a 158% increase was
still evident and 60 min following exercise beta-
endorphin levels were still increased. This exercise-
induced increase in beta-endorphins is highly sig-
nificant (P < 00001) in the asymptomatic patients.
The most important result here is that beta-endor-
phin levels differ significantly (P < 001) between
symptomatic and asymptomatic patients at the point
of maximal exertion, 10 min and 20 minutes after
exercise cessation.
EFFECT OF NALOXONE
After naloxone injection, significant differences
were no longer found between symptomatic and asy-
mptomatic patients on the exercise-induced increase
in beta-endorphin levels (Fig. 2). In both patient
groups, the 6 mg injection of naloxone evoked an
increment in the serum beta-endorphin levels. This
exercise-induced increase in beta-endorphins after
naloxone was larger in the symptomatic patients and
thus nullified the group differences found under
placebo.
PLASMA CORTISOL LEVELS
The time course of plasma cortisol levels exhibited
the same pattern as beta-endorphins with a 10 min
time lag, suggesting a common excretion of both
ACTH as a precursor of cortisol and beta-endorphins
from the hypophysis. Following placebo control
injection, a significant difference is evident between
symptomatic and asymptomatic patients on cortisol
levels, and this difference is nullified by naloxone
(Fig. 2, lower panel). No group differences were evi-
dent on catecholamine levels nor between placebo and
naloxone conditions. Values increased uniformly in
both groups during exercise.
ANGINA PECTORIS PAIN DURING EXERCISE
After 6 mg naloxone i.v. prior to exercise, seven of
eight symptomatic patients reported the occurrence of
angina pectoris with less delay with respect to the
onset of ST segment depression during exercise than
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Figure 2 Comparison of (a) plasma beta-endorphin levels and (b)
cortisol in symptomatic (O. • ) and asymptomatic (A, A) patients
following placebo (O, A) and naloxone ( • . A). Error bars show ± 1
SD of the mean.
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Figure S The effect of naloxone on the onset of angina
pectoris pain during exercise in (a) symptomatic and (b)
asymptomatic patients.
following placebo (P < 005). The time differences
are shown in Fig. 3. The total duration of angina
pectoris was prolonged after naloxone compared to
placebo (405 ± 148 vs. 333 ± 97 s, respectively).
More time was required after termination of exercise
in the naloxone condition before patients were
relieved of angina pectoris (686 ±171 s vs.
658 ± 181s, respectively), although these differences
were not significant.
In the naloxone condition, two asymptomatic
patients, who had never before experienced angina
pectoris during ST segment depression under exer-
cise, reported typical angina pectoris symptoms. The
severity of their discomfort and the magnitude of the
ST segment depression in these two patients was such
that exercise did not need to be prematurely ter-
minated. One of these patients reported occasional
occurrences of angina pectoris during everyday life,
whereas the other was completely free of subjective
symptoms. Angina pectoris could not be provoked
in the other seven asymptomatic patients after 6 mg
naloxone injection.
EXPERIMENTAL PAIN THRESHOLDS
Ischaemic pain thresholds significantly differed
between symptomatic and asymptomatic patients
[Fig. 4(a)]. Symptomatic patients reported having
 at U
niversitaetsbibliothek Regensburg on July 20, 2012
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
30 C. Drosie et al.
Rest Exercise Rest Exercise
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Figure 4 Comparison of (a) ischaemic and (b) electrical
pain tests in symptomalic and asymptomatic patients.
pain 73-8 s, on average, following cuff inflation and
the start of exercise, whereas asymptomatic patients
required a mean of 112.1 sec before they felt pain.
This difference is highly significant (P < 001) and
corresponds well with the findings of our earlier
study'16'171. A moderate, but not significant, in-
crease in ischaemic pain thresholds was found after
exercise. Following naloxone injection and after
exercise, asymptomatic (109-8s) and especially
symptomatic (59-1 s) patients required less time to
reach ischaemic pain thresholds. Compared with the
placebo condition, this difference was significant
(P < 002). These differences were especially notice-
able in the two asymptomatic patients who reported
angina pectoris during exercise following naloxone.
Asymptomatic patients exhibited substantially
higher electrical pain thresholds at rest (2-213 mA)
compared with their symptomatic counterparts
[0-793 mA; Fig. 4(b)]. Due to large inter-individual
differences and the small sample size, this difference
did not, however, obtain traditional significance
levels. An exercise-induced elevation in pain thres-
hold was not evident. Directly after exercise, symp-
tomatic patients had a mean threshold of 0-865 mA
and the asymptomatic patients a mean threshold of
2-237 mA. Naloxone did not have a significant effect
on electrical pain thresholds.
Discussion
One of the major findings of the present investi-
gation indicates that during exercise asymptomatic
patients exhibit significantly greater elevations in
beta-endorphins in plasma than do symptomatic
patients. Following injection of 6 mg naloxone this
difference is reduced and no longer statistically signifi-
cant. This finding suggests that excretion of cir-
culating beta-endorphins from the hypophysis is
regulated by an opioid mechanism and that there are
quantitative differences in this opioid control be-
tween symptomatic and asymptomatic patients. The
opioid regulation of ACTH as a precursor of cortisol
has been demonstrated"81. It appears that ACTH
and beta-endorphins are produced in parallel and
that naloxone may affect corticotropic releasing
factors"91.
The finding that beta-endorphin levels are greater
during exercise in asymptomatic patients suggests, at
first glance, that circulating endorphins have a direct
effect on pain thresholds. The results of earlier stud-
ies, however, indicate that such a direct relationship
is probably not the case. There are, for example,
disorders where the beta-endorphin levels are greatly
elevated (e.g. in the Nelson syndrome with levels
ranging from 400-700 pg ml"1), but pain thresholds
are normal. On the other hand, there are cases
reported where the patients have extreme congenital
hypoalgesia but beta-endorphin levels are normal,
although naloxone can reverse these elevated pain
thresholds'71. Intravenous injection of beta-endor-
phins does not have an analgesic effect, even when
given in high doses, although an analgesic effect has
been found after beta-endorphin injection in cerebral
spinal fluid12". The site of beta-endorphinergic
action appears thus most likely to be in the central
nervous system and not in the periphery. Owing to
their high molecular weight, beta-endorphins cannot
pass the blood-brain barrier. It is assumed, however,
that excretion of beta-endorphins by the hypophysis
and changes in central-nervous beta-endorphin levels
are positively correlated'221.
Although a direct effect of beta-endorphins in
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Physical exercise and pain threshold 31
serum on pain regulation is not to be expected, we
assume that a complex, opioid-based pain regulatory
mechanism is involved in the presence or absence of
coronary pain. It should be noted that our asy-
mptomatic and symptomatic patients differ only in
one major way, namely the presence or absence of
pain during adequate stimulation. Table 1 indicates
that the extent of myocardial ischaemia. as well as the
extent of physical exercise reached during testing do
not differ between patient groups and thus cannot
explain the lack of pain in asymptomatic patients.
An analysis of each individual time course indicated
that beta-endorphin levels increased during exercise
in every patient and then returned to normal in
resting. Exercise at approximately 100 W is sufficient
to provoke an increase in beta-endorphins. Thus
typical exercise tests in coronary patients should be
sufficiently strenuous to elicit changes in circulating
beta-endorphins.
It is well known that serum beta-endorphin levels
can be influenced by several factors. We found that a
prolonged resting period at the beginning of the
measurement session, as well as a pretest to let the
patients accommodate themselves to the experi-
mental setting and measurements, is required to
obtain reliable basal values. We also observed that
differences in beta-endorphin determinations can
occur depending on whether the blood-sample can-
nula is chilled or not and whether the blood is
immediately centrifugated and chilled during cent-
rifugation or whether some time elapses between the
time of blood sampling and centrifugation. There are
also differences between the various determination
methods; some kits exhibit a high cross-reaction with
other proteins and thus lead to higher values than
normally found'231.
The method of beta-endorphin determination used
in the present study exhibits a very low cross-reaction
and the rest values measured in our patients corres-
pond well with those in the literature1241. The
analysis of each patient's values indicated that,
compared with the symptomatic patients, eight of the
nine asymptomatic patients tested exhibited a greater
increase in beta-endorphins during exercise. These
differences were nullified by naloxone. The significant
differences between asymptomatic and symptomatic
patients on cortisol suggest that these patients differ
with respect to neuroendocrine regulation.
Earlier studies concerned with the possible role of
endogenous opiates in silent myocardial ischaemia
have brought forth, in part, contradictory results. In
addition to the possible methodological flaws dis-
cussed above, the following aspects may be important
factors with respect to the disparate findings: (1)
most of these studies have tested either symptom-
atjc[25.29] Q r asymptomatic patients'17-23-271 and
(2) they have either been limited to the determination
of plasma beta-endorphins'28"301 or to naloxone
injection11725"271 but not both. The only study1231,
besides the present one. that has combined these
measurements used a relatively unspecific determina-
tion technique (yielding resting values 10 times higher
than normal) and found no increase in circulating
beta-endorphins during exercise. Our results are in
good agreement with the recent work of Specchia
and his coworkers'281, who also found significant
differences in beta-endorphin levels in symptomatic
and asymptomatic patients, and differences in ex-
perimentally determined pain thresholds'311. These
authors found differences already in resting beta-
endorphin levels, which may be related to higher
arousal levels in these patients during testing. The
beta-endorphin levels we found on day 1 during the
pretest, where the patients did not rest for 30 min
prior to blood sampling, also show a tendency to be
higher in the asymptomatic patients.
Another important factor causing the contradic-
tory results apparent in the literature is the criterion
used to assign patients into symptomatic and asympto-
matic groups. As in our earlier studies11732), we
have selected asymptomatic patients based on the
strict criterion that they had never before reported
angina pectons pain during exercise testing. Only two
of our nine asymptomatic patients reported any dis-
comfort during everyday life. Our asymptomatic
patients also exhibit extremely high experimentally
determined pain thresholds, which would presumably
not be the case had we selected patients with less
pronounced asymptomatic myocardial ischaemia.
The same line of reasoning may also hold for the beta-
endorphin differences found here. Since we selected
extreme patient types with respect to the occurrence
or absence of angina pectoris during exercise, the
patient groups exhibit significant differences, which
might not be as clearcut in patients with a mixed
form of myocardial ischaemia having both silent and
painful ischaemic episodes.
A possible explanation for the group differences
on beta-endorphins found here would be that the
differences on endorphin levels are not the cause of
the absence of pain in myocardial ischaemia, but
rather that these differences are the consequence of
the presence or absence of chronic pain in these
patients. There are a number of studies in the litera-
ture which indicate that prolonged chronic pain is
associated with a reduction in the beta-endorphin
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level in cerebrospinal fluid133341. The extent to
which secretion of beta-endorphins in serum is re-
lated to changes in the CSF level of beta-endorphins
has still lo be determined. All of our symptomatic
patients had a long history of angina pectoris pain
having several painful episodes each week for several
years. It could be speculated that such prolonged
pain could lead to a fatiguing of the endorphinergic
system and thus to a lower rate of release or to an
increased rate of metabolism. If this is the case then
the question arises why such a regulative mechanism
does not affect the sensibility of all patients with
myocardial ischaemia, and why asymptomatic pa-
tients appear to be an exception to the general rule.
A possible factor may be found in the earlier clinical
history of the patient, where some patients experience
intense chronic pain and others suppress painful
episodes. If the lower reactivity of endorphinergic
mechanisms to physical exercise in symptomatic
patients found here is related to a prolonged history
of pain, then such a difference appears to be rever-
sible by naloxone, a finding which has not yet been
reported in the literature.
Agonist-induced receptor down-regulation has
been shown to affect the density of adrenergic
receptors. It could be presumed that opioid receptors
may also increase their density depending on the level
of opioids'351. Thus it could be argued that symp-
tomatic and asymptomatic patients may differ with
respect to the density of opioid receptors involved in
the mediation or blocking of nociceptive afferents
from the myocardium. Unfortunately, there is, to our
knowledge, at present no sufficient evidence in the
literature to support such speculation.
The experimental pain thresholds reported here
support our earlier findings'16321 and those of
other research groups131361, namely that asymp-
tomatic patients exhibit higher pain thresholds
than do symptomatic patients, although there is
considerable within-group variance. The finding that
naloxone had an effect on ischaemic pain thresholds
but not on electrical pain thresholds corresponds to
the findings of earlier investigations'91. Our 6 mg
injection of naloxone had an effect, though just barely
significant, on the latency of angina pectoris onset.
Our experimental control in this respect, using a
series of stopwatches and a quiet recording environ-
ment, led to reproducible results. Despite these pre-
cautions, the effect of 6 mg naloxone was small,
which may suggest that larger doses are required or
that nonopioid receptors are involved and that
naloxone does not block specifically enough. Con-
trary to the result expected on the basis of an earlier
study'371, naloxone had no effect on catecholamines
levels during exercise, which would have increased
oxygen consumption, and thus could have led to
group differences between placebo and naloxone
conditions.
In summary, the findings of the present inves-
tigation suggest a possible role for an endorphinergic
mechanism in the control of myocardial ischaemic
pain, although other mechanisms are surely involved.
The greater increase in circulating endorphins found
here in exercising asymptomatic patients may not be,
in itself, the cause of their lacking angina pectoris
pain, but rather reflects a higher reactibility of opioid
mechanisms to stressful stimuli. These differences
between symptomatic and asymptomatic patients are
reversed by naloxone, thus pointing to quantitative
differences in the opioid regulation of pain in these
patient groups.
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